Cpx-351
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
35 Active assets in the Acute Myeloid Leukemia With Myelodysplasia-Related Changes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 3 | BB |
ETOPOSIDE Institut de Recherches Internationales Servier | Phase 2 | BB |
Daunorubicin Institut de Recherches Internationales Servier | Phase 3 | BB |
Decitabine National Cancer Institute (NCI) | Phase 3 | BB |
ag-120 Institut de Recherches Internationales Servier | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Cpx-351 is also rated in:
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →